Promising new combo targets inflammation in tough pancreatic cancer
NCT ID NCT04926467
First seen Nov 11, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study tests whether adding the anti-inflammatory drug anakinra to standard chemotherapy can help people with pancreatic cancer that can be removed by surgery. About 24 adults with early-stage or locally advanced pancreatic cancer will receive the drug combination before and after surgery. The main goal is to see if the treatment lowers a key tumor marker (CA19-9) and helps patients live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center, Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.